-transparent.png){kind=logo}
Amiodarone, a commonly used antiarrhythmic agent, has numerous adverse effects. The purpose of this case report is to highlight its hepatotoxicity, an unusual complication of long term amiodarone therapy. Our patient is a 76-year-old man with underlying ischaemic heart disease and recurrent ventricular tachycardia. Eleven months after commencing amiodarone, he developed asymptomatic raised aminotransferases which resolved following drug withdrawal. Amiodarone was then reintroduced and four years later, the patient developed hepatomegaly, worsening liver biochemistry and histopathological changes consistent with early cirrhosis. His symptoms improved following discontinuation of amiodarone. However, hepatomegaly and a low serum albumin still persist four years later.
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
July 2008,
Current vascular pharmacology,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 2012,
Hepatology (Baltimore, Md.),
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 1986,
The Netherlands journal of medicine,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 1986,
The New England journal of medicine,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 1997,
Digestive diseases (Basel, Switzerland),
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 1986,
Acta medica Scandinavica,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
January 2007,
Indian heart journal,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
November 2023,
BMJ case reports,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
September 1995,
Minerva medica,
R Jeyamalar, and
R Pathmanathan, and
D Wong, and
P Kannan
April 2012,
European journal of clinical pharmacology,
